Live
FierceBiotechEthyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s TepezzaEndpoints NewsShattuck raises $75M; Servier inks neuro ASO pact with n-Lorem FoundationEndpoints NewsBiotech pay analysis: 12 execs with $35M+ M&A golden parachutesBioPharma DiveAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineFierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BBioWorldShenzhen Chipscreen Biosciences synthesizes new HDAC inhibitorsBioWorldKunming Taita Biotech discovers new angiogenesis inhibitorsBioWorldJiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonistsBioWorldColumbia researchers use base editing to modify human embryo genomeLabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptation
BioWorld 6. Jan. 2026

Scinopharm wins US FDA approval of multiple sclerosis drug

Scinopharm wins US FDA approval of multiple sclerosis drug

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.